Growth Disorders

Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.

Also Known As:

Networked: 283 relevant articles (7 outcomes, 21 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Cardiovascular Diseases (Cardiovascular Disease)
2.	Turner Syndrome (Turner's Syndrome)
3.	Dwarfism
4.	Alopecia (Baldness)
5.	Precocious Puberty

Experts

1.	Clayton, Peter E: 8 articles (06/2014 - 06/2006)
2.	Murray, Philip G: 5 articles (06/2014 - 06/2009)
3.	Hanson, Dan: 5 articles (06/2014 - 06/2009)
4.	Black, Graeme C M: 5 articles (06/2014 - 06/2009)
5.	Goździcka-Józefiak, Anna: 4 articles (01/2015 - 07/2003)
6.	Dunkel, Leo: 4 articles (07/2010 - 08/2003)
7.	Ross, Judith L: 3 articles (01/2014 - 06/2002)
8.	Clayton, P E: 3 articles (01/2013 - 01/2002)
9.	Bang, Peter: 3 articles (12/2012 - 01/2004)
10.	Rosenfeld, Ron G: 3 articles (08/2012 - 02/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Growth Disorders:

1.	Human Growth Hormone (Saizen)FDA LinkGeneric 01/01/2013 - "Treatment of children with growth disorders with recombinant human growth hormone is necessary for improved outcomes, including final height. " 12/01/2006 - "The North American (US and Canada) GHMonitor was initiated to assess the safety and efficacy of Saizen (somatropin [recombinant human growth hormone for injection]) for growth disorders. " 01/01/2013 - "Adherence data from the Observational Study Saizen®-online, recorded with the easypod™ device collected between October 2009 and May 2011, were analyzed in pediatric patients receiving recombinant human growth hormone treatment for a variety of growth disorders. " 11/01/2014 - "Recombinant human growth hormone (rhGH) availability has allowed the treatment of a greater number of growth disorders. " 05/01/2012 - "Recombinant human growth hormone (rhGH) therapy is used in the long-term treatment of children with growth disorders, but there is considerable treatment response variability. "
2.	Insulin-Like Growth Factor I (IGF-1)IBA 06/01/2012 - "Future studies will provide new insight into IGF-I as treatment and into the nature of growth disorders that involve the IGF axis." 05/01/1999 - "This study demonstrates that although urinary IGF-I has no place in the diagnosis of growth disorders, in normal children there is a highly significant relationship between serum and urinary IGF-I with levels of each changing in a similar manner through childhood and adolescence. " 05/01/1999 - "The aims of this study were to investigate the correlation between serum and urinary IGF-I in normal children and compare their use in the evaluation of growth disorders. " 04/01/1986 - "Thus, analysis of erythrocyte IGF-I binding and receptor phosphorylation may be useful tools for the study of patients with a variety of growth disorders." 01/01/2015 - "Attention was also drawn to the directions of use of IGf-1 in the treatment of other diseases than the diseases of the hypothalamic-pituitary and growth disorders in children. "
3.	Insulin (Novolin)FDA Link 06/01/1996 - "rhIGF-I offers promise in the treatment of selective growth disorders and in protein catabolic and insulin-resistant states." 01/01/2013 - "Insulin-like growth factor 1 (IGF1) is an important biomarker of human growth disorders that is routinely analyzed in clinical laboratories. " 01/01/2014 - "Combined therapy with insulin and growth hormone in 17 patients with type-1 diabetes and growth disorders." 02/01/2011 - "Growth hormone remains the mainstay of therapy for growth disorders, though other options, including recombinant insulin-like growth factor 1, are being investigated in various settings." 12/01/2007 - "Insulin-like growth factor 1 (IGF-I) and organochlorine pesticides (OCs) have been involved in the pathogenesis of several diseases like cancer, diabetes and growth disorders. "
4.	Insulin-Like Growth Factor Binding Protein 3IBA 01/01/1990 - "A specific radioimmunoassay for insulin-like growth factor-binding protein 3 (IGFBP-3), developed against its binding subunit (IGFBP-3 beta), was used to investigate its diagnostic potential for the evaluation of growth disorders. " 01/01/1990 - "Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders." 01/01/2012 - "Our reference value model based on age, sex, and pubertal stage can improve the diagnostic utility of IGF-1 and IGFBP-3 levels in the evaluation and management of Korean children and adolescents with growth disorders." 09/01/2009 - "Establishment of reference serum IGF-I and IGFBP-3 ranges during childhood and adolescence in Tunisian subjects can help to enhance the diagnostic efficiency of IGF-I and IGFBP-3 in evaluating growth disorders in our population." 01/01/2006 - "Establishment of this reference data and a standard deviation score prediction model based on age, sex and puberty will enhance the diagnostic power and utility of IGF-I and IGFBP-3 in evaluating growth disorders in our population."
5.	Aromatase InhibitorsIBA 01/01/2009 - "Update on the role of aromatase inhibitors in growth disorders." 08/01/2003 - "Because new P450 aromatase inhibitors may prove to be potential drugs in various growth disorders, the effect of suppression of E action on developing peak bone mass has to be closely evaluated. " 09/01/2006 - "Aromatase inhibitors, a novel treatment modality for some growth disorders, may significantly influence these risk factors for cardiovascular disease by suppressing oestrogen biosynthesis and stimulating gonadal androgen production. " 07/01/2010 - "Aromatase inhibitors (AIs), blockers of estrogen biosynthesis, delay bone maturation and therefore are used increasingly to promote growth in children and adolescents with growth disorders. "
6.	SteroidsIBA 10/01/1963 - "[THE EFFICACY OF ANABOLIC STEROIDS AS CORRECTIVES OF GROWTH DISORDERS]." 07/09/1990 - "[Inhaled steroids and growth disorders]." 01/01/1993 - "The original list of indications for anabolic-androgenic steroids has been reduced to those discussed in this publication so far and to mammary carcinoma, deficiency states and growth disorders. " 09/20/1962 - "[The treatment of growth disorders with anabolic steroids and growth hormone]."
7.	Carrier Proteins (Binding Protein)IBA 07/01/1990 - "wt 53kD) appears to possess a role in growth disorders, whereas the growth hormone independent binding protein (mol. " 01/01/2007 - "In the more common craniosynostosis syndromes and other skeletal growth disorders, the mutations were identified in the genes encoding fibroblast growth factor receptor types 1-3 (FGFR1, 2 and 3) where they are dominantly acting and affect specific and important protein binding domain. " 09/01/2014 - "The measurement of insulin-like growth factors (IGF-I) and insulin-like growth factor-binding protein (IGFBP-3) often serves as first-line testing in children with growth disorders. " 05/01/2006 - "iPlex (mecasermin rinfabate), an equimolar mixture of IGF-I and its binding protein IGFBP-3, was developed to prolong the half-life and to counteract acute adverse events (particularly hypoglycaemia) associated with administration of IGF-I. Although there are no published data on the efficacy of mecasermin rinfabate in treating growth disorders, it does appear that mecasermin rinfabate has a longer half-life in patients with GHIS than unbound IGF-I, and fewer reports of adverse events (including hypoglycaemia) when administered to patients with diabetes."
8.	Estrogens (Estrogen)FDA Link 01/01/2013 - "A better understanding of estrogen-GH interplay in liver will lead to improved therapy of children with growth disorders and of adults with GH deficiency." 10/01/2006 - "While defining major open questions, unsolved clinical challenges, and particularly promising research avenues in this area, we argue that the time has come to pay estrogen-mediated signaling the full attention it deserves in future endocrinological therapy of common hair growth disorders." 07/01/2010 - "Aromatase inhibitors (AIs), blockers of estrogen biosynthesis, delay bone maturation and therefore are used increasingly to promote growth in children and adolescents with growth disorders. "
9.	myotrophin (Increlex)FDA Link 01/01/2005 - "The most advanced indication in development of mecasermin rinfabate is the treatment of severe growth disorders due to growth hormone insensitivity syndrome (GHIS), also called Laron syndrome. " 05/01/2006 - "iPlex (mecasermin rinfabate), an equimolar mixture of IGF-I and its binding protein IGFBP-3, was developed to prolong the half-life and to counteract acute adverse events (particularly hypoglycaemia) associated with administration of IGF-I. Although there are no published data on the efficacy of mecasermin rinfabate in treating growth disorders, it does appear that mecasermin rinfabate has a longer half-life in patients with GHIS than unbound IGF-I, and fewer reports of adverse events (including hypoglycaemia) when administered to patients with diabetes."
10.	IGF-I-IGFBP-3 complexFDA Link 05/01/2006 - "iPlex (mecasermin rinfabate), an equimolar mixture of IGF-I and its binding protein IGFBP-3, was developed to prolong the half-life and to counteract acute adverse events (particularly hypoglycaemia) associated with administration of IGF-I. Although there are no published data on the efficacy of mecasermin rinfabate in treating growth disorders, it does appear that mecasermin rinfabate has a longer half-life in patients with GHIS than unbound IGF-I, and fewer reports of adverse events (including hypoglycaemia) when administered to patients with diabetes."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 06/01/2014 - "The findings provide insight into a possible mechanism underlying hair growth disorders and can be useful for future studies on hair follicle response to insults, such as chemotherapy and ionizing radiation." 08/10/1991 - "Side effects of pharmacotherapy include suppression of the adrenal cortical function and growth disorders, together with truncal obesity, formation of striae of distension or osteoporosis." 07/01/2001 - "In animal studies of hair growth disorders, topical tacrolimus induces anagen and protects from chemotherapy-induced alopecia. "
2.	Radiotherapy 06/01/1979 - "Limited surgical excision is rarely possible and high-dose radiotherapy to the bony pelvis may cause severe and disabling growth disorders. " 06/01/1973 - "[Skeletal growth disorders following radiotherapy and their treatment]." 01/01/2009 - "Long-term radiotherapy-related complications in children with head and neck cancer have been frequently reported, especially facial growth disorders and dental abnormalities. " 12/01/1995 - "[Growth disorders after radiotherapy of Hodgkin's disease in childhood]." 12/03/1999 - "Growth charts presented here can be useful in neurofibromatosis clinics for the identification of the effects of secondary growth disorders, for growth prognosis, and for the evaluation of the effects of a therapy such as GH therapy after radiotherapy for optic glioma."
3.	Transplants (Transplant) 12/01/2002 - "In order to investigate growth disorders associated with osteochondral rib grafts in children, overgrown grafts were examined histologically. " 01/01/1954 - "[Growth disorders in the long bones following taking of bone grafts]."
4.	Transplantation (Transplant Recipients) 06/01/2012 - "Transplantation of the composite scaffold in combination with MSCs and chondrocytes led to the prevention of growth disorder and angular deformity in the distal epiphysis of the left femur. " 01/01/1958 - "[Cartilage joint transplantation in growth disorders caused by radium needles]."
5.	Fat-Restricted Diet (Diet, Fat Restricted) 04/07/1967 - "[Low-fat diet as a cause of growth disorders in infants]."